Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549  

FORM 8-K  

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 9, 2017

American Renal Associates Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37751		27-2170749
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

500 Cummings Center, Suite 6550 Beverly, Massachusetts		01915
(Address of registrant’s principal executive office)		(Zip code)

[phone]

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☒	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.	☒

---

Item 2.02	Results of Operations and Financial Condition.

 

On May 9, 2017 , American Renal Associates Holdings, Inc. issued a press release announcing its financial and operating results for the first quarter ended March 31, 2017 .  A copy of the press release is furnished with this report as Exhibit 99.1 and is incorporated by reference into this item.

 

As provided in General Instruction B.2 of Form 8-K, the information and exhibit contained in this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. 

Item 9.01.	Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit Number		Description
99.1		Press release, dated May 9, 2017, announcing the registrant’s financial and operating results for the first quarter ended March 31, 2017.

---

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				AMERICAN RENAL ASSOCIATES HOLDINGS, INC.
Dated: May 9, 2017				By:		/s/ Jonathan L. Wilcox
				Name:		Jonathan L. Wilcox
				Title:		Chief Financial Officer

---

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press release, dated May 9, 2017, announcing the registrant’s financial and operating results for the first quarter ended March 31, 2017.